Our center also initiated a multicenter, prospective, randomized controlled study (NCT06304987) to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 blockade (Sintilimab) and a PCSK9 inhibitor (Tafolecimab) for treating pMMR/MSS locally advanced rectal cancer (LARC). The gene discussed is PDCD1; the disease is rectal cancer.